Crinetics Pharmaceuticals (CRNX) entered into a merger agreement with Vertex Pharmaceuticals on July 6, 2026, as part of which Vertex will acquire the company. In connection with the merger, Crinetics signed one-year non-compete agreements with its CEO, CFO, Chief Scientific Officer, and Chief Commercial Officer. The CFO, Chief Scientific Officer, and Chief Commercial Officer will receive cash payments of $140,000, $30,000, and $30,000, respectively, when the deal closes.

View Full Filing (SEC EDGAR)

2026-07-06

Crinetics Pharmaceuticals has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals in an all-cash deal. Shareholders will receive $85.00 per share. The merger, approved unanimously by Crinetics' board, is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding CRINETICS PHARMACEUTICALS IN (CRNX)?

Major stakeholders currently include FMR LLC ($572.4M), BlackRock, Inc. ($308.0M), Farallon Capital Management LLC ($302.8M). Based on the latest 13F filings, there are a total of 243 tracked investment funds and institutions maintaining positions in CRNX.

What is the overall institutional sentiment toward CRNX recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $786.6M, driven by 157 managers accumulating shares while 108 reduced their exposure.

Which institutions have been selling or reducing their CRNX positions?

In the latest period, 61 funds trimmed their holdings, and 47 managers completely exited their positions. The aggregate reported sell value was $800.2M.

Are there any notable investors adding CRNX to their portfolios?

Yes, buying activity remains notable. 40 institutions opened new positions in {ticker}, and 117 existing holders added to their shares. The total reported buy value for the quarter amounted to $3.5B.